Insider Transactions in Q1 2021 at Stoke Therapeutics, Inc. (STOK)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 02
2021
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
5,195
-10.3%
|
$322,090
$62.99 P/Share
|
|
Mar 02
2021
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
5,195
+16.37%
|
$0
$0.6 P/Share
|
|
Mar 01
2021
|
Arthur A Levin |
SELL
Open market or private sale
|
Direct |
12,500
-80.17%
|
$750,000
$60.84 P/Share
|
|
Mar 01
2021
|
Arthur A Levin |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+39.06%
|
$0
$0.47 P/Share
|
|
Feb 23
2021
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
5,000
-89.25%
|
$290,000
$58.6 P/Share
|
|
Feb 23
2021
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+47.16%
|
$20,000
$4.48 P/Share
|
|
Feb 22
2021
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
25,000
-55.7%
|
$1,475,000
$59.32 P/Share
|
|
Feb 22
2021
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+49.41%
|
$100,000
$4.48 P/Share
|
|
Feb 19
2021
|
Arthur Tzianabos |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$600,000
$60.67 P/Share
|
|
Feb 19
2021
|
Arthur Tzianabos |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.19 P/Share
|
|
Jan 06
2021
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
32
-100.0%
|
$1,824
$57.14 P/Share
|
|
Jan 04
2021
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-63.24%
|
$336,300
$59.26 P/Share
|
|
Jan 04
2021
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+49.86%
|
$11,400
$2.19 P/Share
|